S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.27 (-2.65%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.27 (-2.65%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.27 (-2.65%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
S&P 500   3,248.39 (-2.03%)
DOW   26,815.14 (-1.73%)
QQQ   265.27 (-2.65%)
AAPL   107.91 (-3.49%)
MSFT   202.15 (-2.54%)
FB   250.20 (-1.79%)
GOOGL   1,416.26 (-2.98%)
AMZN   3,022.93 (-3.39%)
NVDA   490.71 (-2.93%)
TSLA   380.46 (-10.32%)
BABA   273.76 (-0.56%)
CGC   14.35 (-10.54%)
GE   6.16 (-1.44%)
MU   50.00 (+0.60%)
AMD   75.29 (-3.10%)
T   28.04 (-1.65%)
F   6.70 (-1.18%)
ACB   5.23 (-28.55%)
GILD   63.53 (+0.21%)
NFLX   473.76 (-3.54%)
DIS   123.66 (-2.79%)
BAC   23.58 (-1.50%)
BA   152.44 (-2.78%)
Log in
NASDAQ:FATE

Fate Therapeutics Price Target, Predictions & Analyst Ratings

$36.67
-0.42 (-1.13 %)
(As of 09/23/2020 02:52 PM ET)
Add
Compare
Today's Range
$36.22
Now: $36.67
$37.30
50-Day Range
$30.41
MA: $34.70
$39.25
52-Week Range
$12.59
Now: $36.67
$39.44
Volume27,399 shs
Average Volume1.03 million shs
Market Capitalization$3.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.69

Analyst Ratings

Fate Therapeutics (NASDAQ:FATE) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
14 Wall Street analysts have issued ratings and price targets for Fate Therapeutics in the last 12 months. Their average twelve-month price target is $38.07, predicting that the stock has a possible upside of 3.81%. The high price target for FATE is $59.00 and the low price target for FATE is $25.00. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
FATE Consensus Rating: BuyBuyBuyBuy
FATE Consensus Rating Score: 2.932.932.942.88
FATE Analyst Ratings: 0 Sell Rating(s)
1 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
FATE Consensus Price Target: $38.07$37.44$36.35$34.18
FATE Price Target Upside: 3.81% upside9.76% upside11.10% upside20.98% upside

Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/13/2020Cantor FitzgeraldBoost Price TargetOverweight$32.00 ➝ $40.00Low
8/6/2020HC WainwrightReiterated RatingBuy$42.00Medium
8/6/2020OppenheimerReiterated RatingBuy$40.00High
6/9/2020Piper SandlerLower Price Target$63.00 ➝ $59.00Low
5/12/2020BMO Capital MarketsBoost Price TargetMarket Perform$28.00 ➝ $29.00High
4/3/2020WedbushBoost Price TargetOutperform$38.00 ➝ $41.00High
4/3/2020MizuhoReiterated RatingBuy$40.00High
3/4/2020CitigroupBoost Price TargetBuy$26.00 ➝ $41.00High
3/4/2020BarclaysInitiated CoverageOverweight$40.00High
3/3/2020Roth CapitalBoost Price Target$20.00 ➝ $30.00High
3/3/2020BTIG ResearchBoost Price TargetBuy$27.00 ➝ $42.00High
3/3/2020GuggenheimBoost Price TargetBuy$25.00 ➝ $41.00High
2/12/2020Wells Fargo & CompanyReiterated RatingOverweight$24.00 ➝ $34.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$25.00Low
9/30/2019Stifel NicolausInitiated CoverageBuy$27.00High
9/16/2019Piper Jaffray CompaniesLower Price TargetOverweight$30.00 ➝ $28.00Low
7/12/2019CIBCInitiated CoverageOutperform ➝ Outperform$27.00High
3/28/2019SVB LeerinkInitiated CoverageOutperform$20.00Medium
1/3/2019StephensDowngradeOverweight ➝ EqualMedium
11/5/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$17.00Low
3/6/2018UBS GroupDowngradeOutperform ➝ Market PerformHigh
12/12/2017Raymond JamesReiterated RatingBuyMedium
(Data available from 9/23/2018 forward)
This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.